EPISODE · Mar 17, 2023 · 1H 18M
Additional Advances in NSCLC Research and Clinical Trials With Ticiana Leal, MD
from Oncology Data Advisor · host i3 Health
Click here to view and claim credit for Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/oda-nsclc-immunotherapy Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With numerous developments in the field occurring since recording the activity, including new FDA approvals and clinical trial results, Dr. Leal sat down with Oncology Data Advisor to provide an update on the rapidly evolving field of NSCLC immunotherapy.
What this episode covers
Click here to view and claim credit for Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/oda-nsclc-immunotherapy Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With numerous developments in the field occurring since recording the activity, including new FDA approvals and clinical trial results, Dr. Leal sat down with Oncology Data Advisor to provide an update on the rapidly evolving field of NSCLC immunotherapy.
NOW PLAYING
Additional Advances in NSCLC Research and Clinical Trials With Ticiana Leal, MD
No transcript for this episode yet
Similar Episodes
Jun 20, 2026 ·2m
Jun 15, 2026 ·3m
Jun 14, 2026 ·2m
Jun 13, 2026 ·3m
Jun 12, 2026 ·3m
Jun 11, 2026 ·3m